Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial
Zinman B, Bhosekar V, Busch R, et al.
The Lancet Diabetes and Endocrinology. Pub. online 1 March 2019
Leggi
Zinman B, Bhosekar V, Busch R, et al.
The Lancet Diabetes and Endocrinology. Pub. online 1 March 2019
Leggi
Sharma A, Coles A, Sekaran NK, et al.
J Am Coll Cardiol. 2019;73(8):893-902
Leggi
Thondapu V, Kurihara O, Yonetsu T, et al.
American Journal of Cardiology. Pub. online 22 February 2019
Leggi
Kurihara O, Thondapu V, Kim HO, et al.
American Journal of Cardiology. Pub. online 22 February 2019
Leggi
Ceriello A, Monnier L, Owens D
Lancet Diabetes Endocrinol. 2019;7(3):221-30
Leggi
Smit JM, Mahdiui ME, van Rosendael AR, et al.
American Journal of Cardiology. Pub. online 22 February 2019
Leggi
Brown TJ, Mead E, Ells LJ
JAMA Pediatr. Pub. online ,18 February 2019
Leggi
Fottrell E, Ahmed N, Morrison J, et al.
Lancet Diabetes Endocrinol. 2019;7(3):200-12
Leggi
Ringholm L, Roskjær AB, Engberg S, et al.
Diabetologia. 2019;62(3):387-98
Leggi
Lin CY, Hsieh MC, Kor CT, Hsieh YP
Diabetologia. 2019;62(3):438-47
Leggi